The global antidiabetics market is influenced by the growing burden of obesity and related metabolic conditions. Demand for therapies that support glucose control and weight management has encouraged pharmaceutical companies to invest in incretin-based medicines and other treatment approaches. The antidiabetics market is projected to reach US$ 187.69 billion by 2031, registering a CAGR of 9.0%...